Multiple Sclerosis and Oligodendrocytes: The Target of Autoimmune Attack
MS is characterized by immune‑mediated destruction of oligodendrocytes—the cells that produce and maintain myelin in the CNS. Loss of oligodendrocytes leads to demyelination, impaired saltatory conduction, and neurodegeneration.
Pathology
- Activated T cells (CD4+ Th1/Th17) and B cells cross the blood‑brain barrier.
- Inflammatory cytokines (IFN‑γ, TNF‑α, IL‑17) and antibodies damage oligodendrocytes.
- Remyelination attempts occur but are often incomplete, especially with age.
Therapeutic Targets
DMTs aim to reduce inflammation (e.g., anti‑CD20, S1P modulators). Emerging strategies promote remyelination (clemastine, opicinumab trials) and neuroprotection.
Multiple Sclerosis - Related Articles
- Managing Relapsed/Refractory Multiple Myeloma: Treatment Options & Strategies
- Managing Hearing Loss Associated with Multiple Sclerosis
- Managing Muscle Spasms in Multiple Sclerosis: Causes & Treatments
- What’s the Best Climate for You If You Have Multiple Sclerosis?
- Multiple Sclerosis (MS) Symptoms: What to Watch For
- Multiple Sclerosis Progression and Its Impact on Life Expectancy
- Multiple Sclerosis Treatment Updates: A Comprehensive Overview
